Physician

Internal Medicine

Dr. Carol A. Hartley, MD

Doctor Carol A. Hartley, MD works in the field of Internal Medicine. She went to medical school at Oregon Health & Science University School of Medicine. She received 1 awards: "Meaningful Use Stage 1 Certification". Carol Hartley is also a published MD. She has 38 paper published. The most recent paper is: Changes in the hemagglutinin molecule of influenza type A (H3N2) virus associated with increased virulence for mice.

Publications

Comparative analysis of the complete genome sequences of two Australian origin live attenuated vaccines of infectious laryngotracheitis virus.
Mapping B-cell epitopes in equine rhinitis B viruses and identification of a neutralising site in the VP1 C-terminus.
Horizontal transmission dynamics of a glycoprotein G deficient candidate vaccine strain of infectious laryngotracheitis virus and the effect of vaccination on transmis...
Equine rhinitis A virus-like particle expressing DNA vaccine induces a virus neutralising immune response in mice.
First complete genome sequence of infectious laryngotracheitis virus.
Several recombinant capsid proteins of equine rhinitis a virus show potential as diagnostic antigens.
Comparison of antibody detection assays for the diagnosis of equine herpesvirus 1 and 4 infections in horses.
Transforming growth factor beta inhibits the action of stem cell factor on mouse and human hematopoietic progenitors.
Changes in the hemagglutinin molecule of influenza type A (H3N2) virus associated with increased virulence for mice.
Human immunodeficiency virus grown in CD4-expressing cells is associated with CD4.
A serum mannose-binding lectin mediates complement-dependent lysis of influenza virus-infected cells.
Bovine and mouse serum beta inhibitors of influenza A viruses are mannose-binding lectins.
Two distinct serum mannose-binding lectins function as beta inhibitors of influenza virus: identification of bovine serum beta inhibitor as conglutinin.
Complement-dependent neutralization of influenza virus by a serum mannose-binding lectin.
The nucleotide sequence of the glycoprotein G homologue of equine herpesvirus 3 (EHV3) indicates EHV3 is a distinct equid alphaherpesvirus.
Detection of viruses in nasal swab samples from horses with acute, febrile, respiratory disease using virus isolation, polymerase chain reaction and serology.
Outbreak of equine herpesvirus type 1 myeloencephalitis: new insights from virus identification by PCR and the application of an EHV-1-specific antibody detection ELISA.
Identification of equine herpesviruses 1 and 4 by polymerase chain reaction.
Sequence conservation and antigenic variation of the structural proteins of equine rhinitis A virus.
Evidence that Equine rhinitis A virus VP1 is a target of neutralizing antibodies and participates directly in receptor binding.
Reverse transcriptase-polymerase chain reaction for the detection equine rhinitis B viruses and cell culture isolation of the virus.
Glycoprotein G deletion mutants of equine herpesvirus 1 (EHV1; equine abortion virus) and EHV4 (equine rhinopneumonitis virus).
Comparison of the safety and protective efficacy of vaccination with glycoprotein-G-deficient infectious laryngotracheitis virus delivered via eye-drop, drinking water...
Equine rhinitis B virus: a new serotype.
Prevalence of serum neutralising antibody to equine rhinitis A virus (ERAV), equine rhinitis B virus 1 (ERBV1) and ERBV2.
Glycoprotein G is a virulence factor in infectious laryngotracheitis virus.
Equine rhinitis A virus: structural proteins and immune response.
Identification of a neutralizing epitope in the betaE-betaF loop of VP1 of equine rhinitis A virus, defined by a neutralization-resistant variant.
Sialic acid acts as a receptor for equine rhinitis A virus binding and infection.
Mapping epitopes in equine rhinitis A virus VP1 recognized by antibodies elicited in response to infection of the natural host.
Polymorphism of open reading frame 71 of equine herpesvirus-4 (EHV-4) and EHV-1.
Glycoprotein G deficient infectious laryngotracheitis virus is a candidate attenuated vaccine.
Sequence variation divides Equine rhinitis B virus into three distinct phylogenetic groups that correlate with serotype and acid stability.
Comparative in vivo safety and efficacy of a glycoprotein G-deficient candidate vaccine strain of infectious laryngotracheitis virus delivered via eye drop.
Identification of mixed equine rhinitis B virus infections leading to further insight on the relationship between genotype, serotype and acid stability phenotype.
Evaluation of immunological responses to a glycoprotein G deficient candidate vaccine strain of infectious laryngotracheitis virus.
Virion associated proteins of equine rhinitis B virus 1 (ERBV1): the non-structural protein 3C(pro) co-purifies with virions.

Schools

Oregon Health Sciences University
University of Washington

Doctors Specialties

Internal Medicine

Accepted Insurances

Awards

Meaningful Use Stage 1 Certification

Education

University of Washington
Oregon Health & Science University School of Medicine

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Wallace R. Hodges, MD This Doctor is OpenDoctor Recommended.
	Dr. Janice M. Connolly, MD This Doctor is OpenDoctor Recommended.
	Dr. Katherine J. Adler, MD This Doctor is OpenDoctor Recommended.
	Dr. Les M. Berenson, MD
	Dr. Yuli S. McCann, MD This Doctor is OpenDoctor Recommended.
	Dr. Laxminarsimha D. Reddy, MD This Doctor is OpenDoctor Recommended.
	Dr. Dedra S. Buchwald, MD This Doctor is OpenDoctor Recommended.
	Dr. Anna S. Loge, MD This Doctor is OpenDoctor Recommended.
	Dr. Stefano M. Bertozzi, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Kara E. Walter, MD
	Dr. Jay D. Sprenger, MD This Doctor is OpenDoctor Recommended.